slides · global inventory
All filtered slides
Global slide inventory for the active corpus filters, with each row opening the slide detail view.
Corpus coverage
319,975 slides
319,974 are described (100%), so the treemap can explain the corpus instead of just counting files.
- Total slides
- 319,975
- Described
- 319,974
- Pending
- 1
100%ready for canon
Slide type composition
dynamicclickable
Slide type
Showing 319,974 described slides — 100.0% of 319,975 rendered pages
+Context & problem43,76713.7% · 6,592 docs+Data & charts72,62022.7% · 8,666 docs+Meta & navigation45,93614.4% · 9,739 docs+Recommend & act67,04121.0% · 9,324 docs+Cases & evidence31,2569.8% · 6,067 docs+Frameworks2,1230.7% · 1,232 docs+Appendix35,68211.2% · 6,614 docs+Other21,5496.7% · 5,566 docs
Tile area is proportional to slide count. Click a category to open its subtype map.
all document kinds · all orientations
Slide collection
235,681-235,710 of 319,975
04
Includes a headshot of the CEO and a scientific illustration of cellular structures.AstraZeneca | Results Presentation Deck | 42 slides · AstraZeneca
Conference presentation Investor relations Beat · Attention1 hit
05
The slide uses a three-row layout to highlight financial, clinical, and regulatory achievements.AstraZeneca | Results Presentation Deck | 42 slides · AstraZeneca
Conference presentation Investor relations Beat · AttentionLoop · Aha Moment1 hit
06
The slide uses stacked bar charts to show composition and waterfall-style segments for growth analysis.AstraZeneca | Results Presentation Deck | 42 slides · AstraZeneca
Conference presentation Investor relations Beat · NeedLoop · Aha Moment1 hit
07
The slide uses a combination of a bar chart and a map to visualize market growth and reach, emphasizing the strategic importance of emerging markets.AstraZeneca | Results Presentation Deck | 42 slides · AstraZeneca
Conference presentation Investor relations Beat · NeedLoop · Aha Moment1 hit
08
The slide highlights both existing drug expansion and new drug development milestones.AstraZeneca | Results Presentation Deck | 42 slides · AstraZeneca
Conference presentation Investor relations Beat · NeedLoop · Aha Moment1 hit
09
AstraZeneca | Results Presentation Deck | 42 slidesAstraZeneca | Results Presentation Deck | 42 slides · AstraZeneca
Conference presentation Investor relations Beat · NeedLoop · Aha Moment1 hit
10
The table uses CER (Constant Exchange Rate) for change percentages.AstraZeneca | Results Presentation Deck | 42 slides · AstraZeneca
Conference presentation Investor relations Beat · Satisfaction1 hit
11
The table uses CER (Constant Exchange Rate) for growth comparisons.AstraZeneca | Results Presentation Deck | 42 slides · AstraZeneca
Conference presentation Investor relations Beat · Satisfaction1 hit
12
Includes a waterfall chart for net debt movement and specific guidance metrics for revenue, EPS, tax, and FX impact.AstraZeneca | Results Presentation Deck | 42 slides · AstraZeneca
Conference presentation Investor relations Beat · Satisfaction1 hit
13
The slide highlights existing sites, new sites, and areas of increasing investment across North America, Europe, and Asia.AstraZeneca | Results Presentation Deck | 42 slides · AstraZeneca
Conference presentation Investor relations Beat · Satisfaction1 hit
14
Features headshots of Dave Fredrickson and Susan Galbraith alongside a scientific illustration of antibodies.AstraZeneca | Results Presentation Deck | 42 slides · AstraZeneca
Conference presentation Investor relations Beat · Satisfaction1 hit
15
The chart shows revenue breakdown by product over 8 quarters. The right side provides qualitative commentary on specific product performance and regulatory updates.AstraZeneca | Results Presentation Deck | 42 slides · AstraZeneca
Conference presentation Investor relations Beat · Satisfaction1 hit
16
The slide uses a structured list format to map products to their current performance and future clinical trial catalysts.AstraZeneca | Results Presentation Deck | 42 slides · AstraZeneca
Conference presentation Investor relations Beat · Satisfaction1 hit
17
The slide highlights specific clinical trial names and their associated indications, with a focus on the camizestrant program.AstraZeneca | Results Presentation Deck | 42 slides · AstraZeneca
Conference presentation Investor relations Beat · VisualizationLoop · Golden Circle1 hit
18
AstraZeneca | Results Presentation Deck | 42 slidesAstraZeneca | Results Presentation Deck | 42 slides · AstraZeneca
Conference presentation Investor relations Beat · VisualizationLoop · Golden Circle1 hit
19
Slide 19 of a presentation; includes revenue charts for CVRM and R&I segments and a list of key Q4 2024 dynamics.AstraZeneca | Results Presentation Deck | 42 slides · AstraZeneca
Conference presentation Investor relations Beat · VisualizationLoop · Golden Circle1 hit
20
The slide uses a structured table format to map specific drug brands to their growth drivers and strategic expansion plans.AstraZeneca | Results Presentation Deck | 42 slides · AstraZeneca
Conference presentation Investor relations Beat · VisualizationLoop · Golden Circle1 hit
21
The slide content is obscured by a large grey box, leaving only the title visible.AstraZeneca | Results Presentation Deck | 42 slides · AstraZeneca
Conference presentation Investor relations Beat · VisualizationLoop · Golden Circle1 hit
22
AstraZeneca | Results Presentation Deck | 42 slidesAstraZeneca | Results Presentation Deck | 42 slides · AstraZeneca
Conference presentation Investor relations Beat · VisualizationLoop · Golden Circle1 hit
23
The chart shows a stacked bar breakdown of revenue by product (Ultomiris, Soliris, Strensiq, Koselugo PS, Koselugo CR, Other) across 8 quarters.AstraZeneca | Results Presentation Deck | 42 slides · AstraZeneca
Conference presentation Investor relations Beat · VisualizationLoop · Golden Circle1 hit
24
The slide uses a structured list format to detail growth strategies for three specific pharmaceutical products.AstraZeneca | Results Presentation Deck | 42 slides · AstraZeneca
Conference presentation Investor relations Beat · VisualizationLoop · Golden Circle1 hit
25
The slide highlights a pipeline of NMEs (New Molecular Entities) with specific focus on complement biology.AstraZeneca | Results Presentation Deck | 42 slides · AstraZeneca
Conference presentation Investor relations Beat · VisualizationLoop · Golden Circle1 hit
26
AstraZeneca | Results Presentation Deck | 42 slidesAstraZeneca | Results Presentation Deck | 42 slides · AstraZeneca
Conference presentation Investor relations Beat · Action1 hit
27
The slide uses a three-column layout with icons to represent strategic pillars.AstraZeneca | Results Presentation Deck | 42 slides · AstraZeneca
Conference presentation Investor relations Beat · Action1 hit
28
AstraZeneca | Results Presentation Deck | 42 slidesAstraZeneca | Results Presentation Deck | 42 slides · AstraZeneca
Conference presentation Investor relations Beat · Action1 hit
29
The slide uses a three-column layout with icons to represent financial and operational goals.AstraZeneca | Results Presentation Deck | 42 slides · AstraZeneca
Conference presentation Investor relations Beat · Action1 hit
30
AstraZeneca | Results Presentation Deck | 42 slidesAstraZeneca | Results Presentation Deck | 42 slides · AstraZeneca
Conference presentation Investor relations 1 hit
31
The slide uses icons to represent different medical conditions and color-coding for therapeutic areas (Oncology, BioPharma, Rare Disease).AstraZeneca | Results Presentation Deck | 42 slides · AstraZeneca
Conference presentation Investor relations 1 hit
32
The slide uses color-coding to distinguish between Oncology, BioPharma, and Rare Disease indications.AstraZeneca | Results Presentation Deck | 42 slides · AstraZeneca
Conference presentation Investor relations 1 hit
33
Includes a footnote detailing partner medicines and core financial measure adjustments.AstraZeneca | Results Presentation Deck | 42 slides · AstraZeneca
Conference presentation Investor relations 1 hit